MDSL
GILD icon

M.D. Sass LLC’s Gilead Sciences GILD Stock Holding History

M.D. Sass LLC’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-308,280
Closed -$23.2M – 45
2018
Q1 		$23.2M Sell
308,280
-9,470
-3% -$753K 2.71% 21
2017
Q4 		$22.8M Sell
317,750
-28,765
-8% -$2.18M 2.04% 25
2017
Q3 		$28.1M Sell
346,515
-289,305
-46% -$22.1M 2.35% 16
2017
Q2 		$45M Buy
635,820
+110,320
+21% +$7.34M 2.94% 16
2017
Q1 		$35.7M Buy
525,500
+474,800
+936% +$33.4M 1.86% 26
2016
Q4 		$3.63M Buy
50,700
+2,000
+4% +$149K 0.2% 39
2016
Q3 		$3.85M Sell
48,700
-4,000
-8% -$325K 0.22% 32
2016
Q2 		$4.39M Sell
52,700
-1,000
-2% -$88.7K 0.22% 43
2016
Q1 		$4.93M Sell
53,700
-508
-0.9% -$45.8K 0.26% 35
2015
Q4 		$5.49M Buy
54,208
+3
+0% +$312 0.3% 35
2015
Q3 		$5.32M Sell
54,205
-197
-0.4% -$21.9K 0.29% 32
2015
Q2 		$6.37M Buy
54,402
+2
+0% +$219 0.32% 31
2015
Q1 		$5.34M Buy
+54,400
New +$5.52M 0.27% 33

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

M.D. Sass LLC's GILD Position: Q2 2018 in Review

M.D. Sass LLC sold out of Gilead Sciences (GILD) in Q2 2018, closing a stake of 308,280 shares — an estimated $23.2M sold.

M.D. Sass LLC first reported a position in GILD in Q1 2015 and held it in 13 quarters. The position peaked at $45M in Q2 2017. 1,522 funds tracked by Wall St. Rank hold GILD as of Q2 2018.

  • M.D. Sass LLC reported no remaining Gilead Sciences position as of Q2 2018 after selling out during the quarter.
  • M.D. Sass LLC sold 308,280 Gilead Sciences shares in Q2 2018, an estimated $23.2M.
  • M.D. Sass LLC first reported a position in Gilead Sciences in Q1 2015 and held it in 13 quarters.
  • M.D. Sass LLC's Gilead Sciences position peaked at $45M in Q2 2017.
  • 1,522 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2018.

Based on M.D. Sass LLC's 13F filing for Q2 2018, filed 14 Aug 2018.